



TPI ENTERPRISES LTD. (TPE) – TPE receives two key licence and permit milestones for its European Active Pharmaceutical Ingredient (API) expansion.

(ASX : TPE)

Melbourne, Australia, 6 March 2017.

TPE is pleased to announce that on Friday afternoon 3 March GMT, TPE received the following key regulatory approvals:

1. The final licence from the Portuguese authorities (IAPMEI) to start construction of a 150 tonne multi-purpose Active Pharmaceutical Ingredient (API) manufacturing facility at TPE's facility located at Lisbon, Portugal.
2. An import permit from the UK Home Office to ship Narcotic Raw Material (NRM) to Sterling Pharma for conversion to Codeine Phosphate as part of TPE's toll processing agreement.

Both of these regulatory achievements are central to TPE's strategy of API expansion into the UK, Europe and other open markets including Australia.

The UK market is the largest closed Codeine Phosphate (CPO) market globally with a total of 60 tonnes of CPO consumed annually.

The UK import permit enables TPE to conduct validation batches by the end of 2017 with the expectation of sales commencing on a commercial scale in 2018.

The Portugal licence approval will enable TPE to commence construction with a target to supply commercial batches during the second half of 2018.

For more information please contact

Jarrod Ritchie
Managing Director
TPI Enterprises Limited
+613 93010800

Jaime Pinto
Company Secretary
TPI Enterprises Limited
+613 93010800

About TPI Enterprises Limited

TPI Enterprises Limited (TPI) is one of three licensed poppy processors in Australia, and the only Australian-owned company. It is one of eight processors worldwide producing Narcotic Raw Material for the international pharmaceutical industry. TPI has developed an innovative, efficient and environmentally-sustainable extraction and purification manufacturing process which allows TPI to deliver a highly competitive pricing platform.